关闭
胡庆华
职称:教授
邮箱:huqh@cpu.edu.cn
学院:生命科学与技术学院
实验室:江宁校区学院实验楼一期523室
招生学科:生物学,生物与医药
办公室:江宁校区学院实验楼一期408室
个人简历

1. Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways. Eur Heat J 2023, doi: 10.1093/eurheartj/ehad796. (IF=39.3) 独立通讯

2. Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. Nat Commun 2024 (In press). (IF=16.6) 最后通讯

3. Discovery of novel and potent P2Y14R antagonists via structure-based virtual screening for the treatment of acute gouty arthritis. J Adv Res 2020, 23: 133-142. (IF=10.479) 最后通讯

4. P2Y14 receptor has a critical role in acute gouty arthritis by regulating pyroptosis of macrophages. Cell Death Dis 2020, 11: 394. (IF=8.469) 最后通讯

5. Polysaccharide from Strongylocentrotus nudus eggs regulates intestinal epithelial autophagy through CD36/PI3K-Akt pathway to ameliorate inflammatory bowel disease. Int J Biol Macromol, 2023, 244: 125373. (IF=8.2) 最后通讯

6. GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils. Front Immunol, 2022, 13: 870183. (IF=8.79) 最后通讯

7. Discovery of a Series of 5-Amide-1 H-pyrazole-3-carboxyl Derivatives as Potent P2Y14R Antagonists with Anti-Inflammatory Characters. J Med Chem, 2022, 65: 15967-15990. (IF=7.3) 共同通讯

8. Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy. J Med Chem, 2023, 6: 6315-6332. (IF=7.3) 共同通讯

9. Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. Phytomedicine, 2023, 115: 154851. (IF=7.9) 共同通讯

10. Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y14R antagonists with potential high efficiency against acute gouty arthritis. Eur J Med Chem, 2021, 216: 113313. (IF=7.09) 最后通讯

研究方向

疾病治疗原创靶标发现与新药研发

主持在研项目情况

1、国家重点研发计划(2023YFC2812500),深海贻贝来源生物活性物质的挖掘、功效评价和绿色规模化制造,300万,主持,在研

2、国家自然科学基金面上项目(NSFC82373887),P2Y14R在多发性硬化症中的作用及先导化合物的靶向干预机制研究,49万,主持,在研

3、国家自然科学基金面上项目(NSFC81872867),P2Y6R在动脉粥样硬化中的作用及先导化合物的靶向干预机制研究,55万,主持,已结题

4、国家自然科学基金面上项目(NSFC81773745),P2Y14R对急性痛风性关节炎的调控作用及先导化合物的靶向干预机制研究,61.5万,主持,已结题

5、江苏省自然科学基金面上项目(BK20211223),基于肠上皮细胞程序性坏死探讨P2Y14R靶向治疗缓解炎症性肠病的分子机制,10万,主持,在研

6、科技成果转化(2023年第10号),抗痛风新药的转让及开发,2000万,主持,在研

7、中国药科大学-江阴贝瑞森生化技术有限公司共建实验室合作协议书(校合2019-019),100万,主持,在研

8ZD526鼻喷雾剂临床前药效学研究校合2023-086),60万,主持,在研

9AD制剂(金思维)主要药效学研究校合2020-047),102万,主持,已结题

10、肿瘤类器官在细胞水平和动物水平药物评价模型的开发(校合2019-089),60万,主持,已结题

近年代表性科研成果

1. Macrophage P2Y6 receptor deletion attenuates atherosclerosis by limiting foam cell formation through phospholipase Cβ/store-operated calcium entry/calreticulin/scavenger receptor A pathways. Eur Heat J 2023, doi: 10.1093/eurheartj/ehad796. (IF=39.3) 独立通讯

2. Targeting P2Y14R protects against necroptosis of intestinal epithelial cells through PKA/CREB/RIPK1 axis in ulcerative colitis. Nat Commun 2024 (In press). (IF=16.6) 最后通讯

3. Discovery of novel and potent P2Y14R antagonists via structure-based virtual screening for the treatment of acute gouty arthritis. J Adv Res 2020, 23: 133-142. (IF=10.479) 最后通讯

4. P2Y14 receptor has a critical role in acute gouty arthritis by regulating pyroptosis of macrophages. Cell Death Dis 2020, 11: 394. (IF=8.469) 最后通讯

5. Polysaccharide from Strongylocentrotus nudus eggs regulates intestinal epithelial autophagy through CD36/PI3K-Akt pathway to ameliorate inflammatory bowel disease. Int J Biol Macromol, 2023, 244: 125373. (IF=8.2) 最后通讯

6. GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils. Front Immunol, 2022, 13: 870183. (IF=8.79) 最后通讯

7. Discovery of a Series of 5-Amide-1 H-pyrazole-3-carboxyl Derivatives as Potent P2Y14R Antagonists with Anti-Inflammatory Characters. J Med Chem, 2022, 65: 15967-15990. (IF=7.3) 共同通讯

8. Discovery of Selective P2Y6R Antagonists with High-Affinity and In Vivo Efficacy for Inflammatory Diseases Therapy. J Med Chem, 2023, 6: 6315-6332. (IF=7.3) 共同通讯

9. Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. Phytomedicine, 2023, 115: 154851. (IF=7.9) 共同通讯

10. Design, synthesis and evaluation of 3-amide-5-aryl benzoic acid derivatives as novel P2Y14R antagonists with potential high efficiency against acute gouty arthritis. Eur J Med Chem, 2021, 216: 113313. (IF=7.09) 最后通讯